The Food and Drug Administration recently approved an epilepsy drug derived from marijuana. The approval followed years of research and rigorous clinical testing to tease out the effects and risks associated with the new medication. It’s an example of how high-quality science can lead to new treatments, even when use of the drug is complicated by social and political considerations.
The drug, Epidiolex, is made of cannabidiol (CBD), a component of marijuana that does not produce a high. The CBD in Epidiolex is of pharmaceutical-grade purity and quality. It has been through the same rigorous manufacturing and quality-assurance processes as any other prescription medication.
This is an important point because if you haven’t already, you probably are going to see some social-media posts trying to sell you some CBD oil for “medicinal benefits.”
I even saw a can of CBD-infused sparkling water in the grocery store the other day. The CBD